Frederic Fred Ors

Biography

Fred has served as our Chief Executive Officer since April 2016. As CEO, He has led the transformation of Immunovaccine into a leading clinical stage immune oncology company with world-class collaborators and a strong scientific foundation. He has over 20 years of experience in the biopharmaceutical industry, having served in a number of management roles encompassing business development, intellectual property, strategic planning, pre-marketing and communication. Before joining Immunovaccine, Fred spent 14 years at Medicago serving in many roles of increasing responsibility, most recently as Vice President of Business Development and Strategic Planning. He had been an integral part of Medicago’s success, including securing more than $300M CAN in non-dilutive funding in revenues and future milestones from licensing agreements and government contracts, and the $357M CAN deal acquisition by Mitsubishi Pharma in 2013. Fred served as second Vice-Chair of the Vaccine Industry Committee of Biotech Canada between 2012 and 2016. Prior to Medicago, he was licensing manager at the University Paris VII-Denis Diderot, one of the largest science and medical University in France. He has a B.Sc. degree in Biology and a Master degree in Management from the University of Angers (France).

Research Interest

Fred has served as our Chief Executive Officer since April 2016. As CEO, He has led the transformation of Immunovaccine into a leading clinical stage immune oncology company with world-class collaborators and a strong scientific foundation. He has over 20 years of experience in the biopharmaceutical industry, having served in a number of management roles encompassing business development, intellectual property, strategic planning, pre-marketing and communication. Before joining Immunovaccine, Fred spent 14 years at Medicago serving in many roles of increasing responsibility, most recently as Vice President of Business Development and Strategic Planning. He had been an integral part of Medicago’s success, including securing more than $300M CAN in non-dilutive funding in revenues and future milestones from licensing agreements and government contracts, and the $357M CAN deal acquisition by Mitsubishi Pharma in 2013. Fred served as second Vice-Chair of the Vaccine Industry Committee of Biotech Canada between 2012 and 2016. Prior to Medicago, he was licensing manager at the University Paris VII-Denis Diderot, one of the largest science and medical University in France. He has a B.Sc. degree in Biology and a Master degree in Management from the University of Angers (France).